Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) (WSK-V102)

NCT05765604 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: Recombinant COVID-19 variant vaccine(Sf9 cell)
BIOLOGICAL: Recombinant COVID-19 vaccine(CHO cell)

Sponsor

WestVac Biopharma Co., Ltd.